Story
Fatty liver is mostly driven by insulin resistance and is silent early, and the heart is often what suffers first. What matters is whether the liver is scarring; weight loss is the main treatment, and drugs only add to it.
regulates (2)
Fatty liver is one of the commonest causes of a mildly raised ALT on a routine panel. Liver cells swollen with triglyceride have leaky membranes, and the enzyme escapes into the blood. The reverse does not hold, though: in metabolic dysfunction-associated steatotic liver disease (MASLD), the liver enzyme can be completely normal; a normal liver panel does not rule it out, and whether there is scarring has to be judged with scores such as FIB-4.
Whether the upstream cause is the hepatitis B virus or metabolic fatty liver disease (MASLD), liver injury wakes stellate cells that lay down collagen. The collagen builds up into fibrosis and then cirrhosis, and most liver cancers arise on that ground. Hepatitis B has an extra route: viral DNA integrates into liver cells, so cancer can develop even without cirrhosis.
contrast (1)
There is no solid evidence yet that silymarin treats fatty liver. In a trial in steatohepatitis (fatty liver with inflammation), it missed its primary endpoint. The improvement in fibrosis score was only a secondary finding. The trial had 99 people and judged its results by liver biopsy. The dose was 700 mg three times a day for 48 weeks.